Mûr, Dr A. Payà, Dr M. A. López-Vilchez and Dr R. Carreras (Hospital del Mar, Universidad www.selleckchem.com/PARP.html Autonoma, Barcelona, Spain); Dr N. H. Valerius and Dr V. Rosenfeldt (Hvidovre Hospital, Hvidovre, Denmark); Dr O. Coll, Dr A. Suy and Dr J. M. Perez (Hospital Clínic, Barcelona, Spain); Dr C. Fortuny and Dr J. Boguña (Hospital Sant Joan de Deu, Barcelona, Spain); Dr V. Savasi, Dr S. Fiore and Dr M. Crivelli (Ospedale L. Sacco, Milan, Italy); Dr A. Viganò, Dr V. Giacomet, Dr C. Cerini, Dr C. Raimondi and Professor G. Zuccotti (Department of Pediatrics, L. Sacco Hospital, University of Milan, Milan, Italy); Dr S. Alberico, Dr M. Tropea and Dr C. Businelli (IRCCS

Burlo Garofolo, Trieste, Italy); Dr G. P. Taylor and Dr E. G. H. Lyall (St Mary’s Hospital, London, UK); Ms Z. Penn (Chelsea and Westminster Hospital, London, UK); Drssa W. Buffolano and Dr R. Tiseo (Pediatric Dept, Federico II University,

Naples, Italy), Professor P. Martinelli, Drssa M. Sansone, Dr G. Maruotti and Dr A. AZD1208 cell line Agangi (Obstetric Dept, Federico II University, Naples, Italy); Dr C. Tibaldi, Dr S. Marini, Dr G. Masuelli and Professor C. Benedetto (University di Torino, Torino, Italy); Dr T. Niemieç (National Research Institute of Mother & Child, Warsaw, Poland); Professor M. Marczynska, Dr S. Dobosz, Dr J. Popielska and Dr A. Oldakowska (Medical University of Warsaw, Infectious Diseases Hospital, Warsaw, Poland); Dr R. Malyuta, Dr I. Semenenko and Ms T. Pilipenko (ECS Ukraine co-ordinating centre). “
“The aim of the study was to describe the relationship between preterm delivery (PTD; < 37 weeks of gestation)

and antiretroviral Quinapyramine therapy in a single-centre cohort of pregnant women with HIV infection. A retrospective analysis of data for 331 women who received care in a dedicated HIV antenatal clinic between 1996 and 2010 was carried out. Data on first CD4 cell count and viral load (HIV-1 RNA copies/mL) recorded in pregnancy, class and timing of antiretroviral therapy, gestational age at delivery, and risk factors for and causes of PTD were available from a clinical database. Overall, 13.0% of deliveries were preterm, of which 53% were severe preterm (< 34 weeks of gestation). The lowest rate of PTD was observed in women treated with zidovudine monotherapy (6.2%). Higher rates of PTD were observed in women starting combination antiretroviral therapy (cART) in pregnancy compared with women conceiving while on cART [odds ratio (OR) 2.52; 95% confidence interval (CI) 1.22–5.20; P = 0.011]. Of the women who were eligible for zidovudine monotherapy on the basis of CD4 counts and HIV viral load but who were treated with short-term cART to prevent HIV mother-to-child transmission, 28.6% delivered preterm. Women on short-term cART remained at the highest risk of PTD compared with zidovudine monotherapy in multivariate analysis (OR 5.00; 95% CI 1.49–16.79; P = 0.015). The causes of PTD are multiple and poorly understood.